Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBARQ-COLDU and SD
NCT07266402Phase 3Recruiting
- Sponsor
- Celldex Therapeutics
- Start
- Jan 2026
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of barzolvolimab in Cold urticaria (CU), symptomatic dermographism, sponsored by Celldex Therapeutics. Started Jan 2026; status: recruiting.
02
Drugs
barzolvolimab
03
Conditions
Cold urticaria (CU)symptomatic dermographism
Beyond the preview
Go deeper on NCT07266402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266402.